Head to Head Analysis: Travere Therapeutics (NASDAQ:TVTX) and 180 Life Sciences (NASDAQ:ATNF)

Travere Therapeutics (NASDAQ:TVTX) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Travere Therapeutics and 180 Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	0	3	10	0	2.77
180 Life Sciences	0	0	0	0	N/A

Travere Therapeutics presently has a consensus target price of $19.75, indicating a potential upside of 9.60%. Given Travere Therapeutics’ higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than 180 Life Sciences.

Risk & Volatility

Travere Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Insider & Institutional Ownership

4.1% of 180 Life Sciences shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by insiders. Comparatively, 4.1% of 180 Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Travere Therapeutics and 180 Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-82.14%	-269.18%	-54.08%
180 Life Sciences	N/A	-523.62%	-79.41%

Valuation & Earnings

This table compares Travere Therapeutics and 180 Life Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$177.64 million	7.73	-$111.40 million	($2.10)	-8.59
180 Life Sciences	N/A	N/A	-$19.93 million	N/A	N/A

180 Life Sciences has lower revenue, but higher earnings than Travere Therapeutics.

Summary

Travere Therapeutics beats 180 Life Sciences on 6 of the 10 factors compared between the two stocks.

About Travere Therapeutics

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.